# TheraLens - College Review-2 Implementation Status Report

**Project Title**: TheraLens: Machine Learning-Based Forecasting of Emerging Diseases and Future Therapeutic Development  
**Academic Milestone**: College Review-2 Evaluation  
**Assessment Date**: October 11, 2026  
**Implementation Completion Level**: **82.5%** (Exceeds Review-2 Target Threshold of 70%)  

---

## 1. Executive Summary & Verification Dashboard

The TheraLens project has been brought from an exploratory data engineering state (~25% completion at Review-1) to an advanced Applied Machine Learning implementation achieving **82.5% project completion**.

All components required for Review-2 are implemented in modular Python scripts, executed against active project datasets, verified via a 15-test automated pytest suite (100% pass rate), persisted as production model artifacts, and documented with empirical figures and tables.

### Master Implementation Progress Matrix

| Subsystem / Pipeline Component | Target Completion | Current Status | Empirical Evidence & Deliverables |
| :--- | :---: | :---: | :--- |
| **Data Ingestion & Master Inventory** | 100% | **100%** | 12 datasets verified; `data/processed/` long-format datasets generated |
| **Data Preprocessing & Duplication Audit** | 100% | **100%** | Deduplication engine generated 304 unique clinical patterns (`data/processed/symptom_disease_clean.csv`) |
| **Supervised Symptom Disease Classifier** | 85% | **95%** | Benchmarked 4 models; Logistic Regression achieved 1.0000 Accuracy & Macro F1 on held-out test set ($N=61$) |
| **Model Persistence & Inference Interface** | 80% | **90%** | `models/symptom_classifier.joblib` reloaded & verified; `src/inference/predict_disease.py` CLI interface operational |
| **Therapeutic Target & Candidate Prioritization** | 80% | **90%** | Ranked 3,636 targets & 25,650 candidates via multi-attribute Composite Priority Score ($CPS \in [0, 1]$) |
| **Longitudinal Epidemiological Analysis** | 80% | **85%** | 5,426 records harmonized; 224 outbreak surges detected; time-ordered forecasting evaluated on 2015–2024 horizon |
| **Regulatory Timeline Validation & Audit** | 80% | **85%** | Chunked processing of 555,323 master rows; separated 72,277 Phase 4 approvals from 483,046 trials |
| **Future Therapeutic Milestone Forecast** | 70% | **75%** | Industry latency benchmark prototype (DiMasi et al.); documented epistemic limits of "2114" headline |
| **Model Explainability & Interpretability** | 75% | **80%** | Permutation feature importance on held-out test data; transparent mathematical component score decomposition |
| **Automated Testing Suite (Quality Assurance)**| 80% | **90%** | 15 pytest unit/integration tests created & executed with a **100% pass rate** |
| **End-to-End Orchestrator Workflow** | 85% | **90%** | `src/run_theralens.py` CLI orchestrator executes all 6 modules with zero errors in ~55s |
| **OVERALL PROJECT COMPLETION** | **>= 70%** | **82.5%** | **VERIFIED: Exceeds 70% Target with Empirical Evidence** |

---

## 2. Scripts Executed & Operational Verification

The following scripts were implemented, debugged, and executed successfully during this review cycle:

1. `src/models/train_symptom_classifier.py`
   - **Command**: `python src/models/train_symptom_classifier.py`
   - **Result**: Evaluated Dummy, Logistic Regression, Random Forest, SVM. Persisted best model to `models/symptom_classifier.joblib`.
2. `src/models/evaluate_symptom_classifier.py`
   - **Command**: `python src/models/evaluate_symptom_classifier.py`
   - **Result**: Verified model reloadability and held-out test set accuracy (1.0000).
3. `src/inference/predict_disease.py`
   - **Command**: `python src/inference/predict_disease.py --symptoms "chills,vomiting,high_fever,sweating,headache"`
   - **Result**: Correctly predicted Malaria (Score: 0.2794) with top differential candidates and disclaimer.
4. `src/models/prioritize_therapeutic_candidates.py`
   - **Command**: `python src/models/prioritize_therapeutic_candidates.py`
   - **Result**: Ranked 3,636 targets and 25,650 candidates across 37 diseases.
5. `src/analysis/analyze_epidemiological_trends.py`
   - **Command**: `python src/analysis/analyze_epidemiological_trends.py`
   - **Result**: Standardized 5,426 surveillance records, flagged 224 surges, benchmarked Naive/Rolling/Ridge models.
6. `src/analysis/validate_therapeutic_timeline.py`
   - **Command**: `python src/analysis/validate_therapeutic_timeline.py`
   - **Result**: Audited 12,243 FDA approvals and 555k master timeline rows in ~3.8s using chunked streams.
7. `src/analysis/forecast_therapeutic_timeline.py`
   - **Command**: `python src/analysis/forecast_therapeutic_timeline.py`
   - **Result**: Modeled clinical phase transition latencies across 37 diseases with confidence intervals.
8. `src/analysis/explain_model.py`
   - **Command**: `python src/analysis/explain_model.py`
   - **Result**: Generated permutation feature importances and decomposed candidate score contributions.
9. `src/run_theralens.py`
   - **Command**: `python src/run_theralens.py`
   - **Result**: Orchestrated full pipeline across all 6 modules with zero errors; saved `outputs/run_pipeline_summary.json`.
10. `tests/`
    - **Command**: `python -m pytest tests/ -v`
    - **Result**: **15 passed in 2.09s** (100% pass rate).

---

## 3. Actual Outputs & Artifacts Generated

### 3.1 Model Artifacts (`models/`)
- `models/symptom_classifier.joblib` (Best Logistic Regression pipeline)
- `models/symptom_classifier_metadata.json` (Hyperparameters, metrics, random seed)
- `models/feature_names.json` (132 ordered symptom feature names)
- `models/class_labels.json` (41 disease class labels)

### 3.2 Processed Datasets (`data/processed/`)
- `data/processed/symptom_disease_clean.csv` (304 unique clinical patterns)
- `data/processed/disease_target_rankings.csv` (3,636 ranked Open Targets)
- `data/processed/therapeutic_candidate_rankings.csv` (25,650 ranked candidate molecules)
- `data/processed/epidemiological_trends.csv` (5,426 standardized surveillance records)

### 3.3 Visualizations & Evaluation Charts (`outputs/`)
- `outputs/model_evaluation/model_performance_comparison.png`
- `outputs/model_evaluation/confusion_matrix.png`
- `outputs/model_evaluation/disease_class_distribution.png`
- `outputs/model_evaluation/per_class_f1_scores.png`
- `outputs/therapeutic_prioritization/top_candidate_scores.png`
- `outputs/therapeutic_prioritization/score_component_breakdown.png`
- `outputs/therapeutic_prioritization/pchembl_vs_association_scatter.png`
- `outputs/therapeutic_prioritization/disease_target_prioritization_summary.png`
- `outputs/epidemiological_analysis/global_incidence_trends.png`
- `outputs/epidemiological_analysis/outbreak_surge_detection.png`
- `outputs/epidemiological_analysis/forecasting_model_comparison.png`
- `outputs/epidemiological_analysis/cholera_weekly_seasonality.png`
- `outputs/timeline_analysis/timeline_evidence_classification.png`
- `outputs/timeline_analysis/fda_approval_year_distribution.png`
- `outputs/timeline_analysis/cartesian_duplication_impact.png`
- `outputs/timeline_analysis/phase4_milestones_timeline_trend.png`
- `outputs/timeline_analysis/forecast_pipeline_latencies.png`
- `outputs/explainability/top_symptoms_importance.png`
- `outputs/explainability/candidate_contribution_breakdown.png`

### 3.4 Reports & Summaries (`docs/` & `outputs/`)
- `docs/review2_implementation_section.md`
- `docs/review2_results.md`
- `docs/review2_implementation_status.md`
- `docs/future_therapeutic_forecast_limitations.md`
- `outputs/timeline_analysis/timeline_quality_report.txt`
- `outputs/run_pipeline_summary.json`

---

## 4. Known Scientific & Practical Limitations

1. **Synthetic Duplication in Clinical Symptoms**: Raw `symptom_disease.csv` contains 4,657 identical copies of 304 underlying symptom patterns. While our pipeline resolved data leakage by evaluating strictly on unique patterns, real-world clinical presentations contain noise and incomplete reporting not present in synthetic datasets.
2. **First Approval vs. Secondary Indication Timing**: An FDA drug's first approval year reflects its initial market entry, which precedes subsequent label expansions for other diseases. True indication-specific approval years require granular FDA supplemental NDA (sNDA) tracking.
3. **Biopharmaceutical R&D Predictability Horizon**: Machine learning models can reliably project candidate decision windows over 5–15 year horizons based on clinical pipeline phases. Projecting milestones across century scales (e.g., 2114) carries unbounded epistemic uncertainty due to unpredictable scientific paradigms and trial attrition.

---

## 5. Next Steps for Review-3 (Remaining ~17.5%)

1. **Interactive Web Dashboard**: Implement a Streamlit or Next.js web application allowing clinical symptom selection and interactive visual exploration of candidate rankings.
2. **Graph Neural Networks / Molecular Fingerprints**: Incorporate Morgan molecular fingerprints and Graph Neural Networks (GNNs) for direct compound affinity prediction from SMILES chemical structures.
3. **Live ClinicalTrials.gov Integration**: Ingest real-time Phase 1–3 clinical trial recruitment registries to dynamically update pipeline transition probabilities.
